Vincenzo Levi

Dr. Vincenzo Levi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
IDIvano Dones
Ivano Dones
VLVincenzo Levi
Vincenzo Levi
The origin and the neural pathways involved in chronic neuropathic pain are still not extensively understood. For this reason, despite the wide variety of pain medications available on the market, neuropathic pain is challenging to treat. The present therapeutic alternative considered as the gold standard for many kinds of chronic neuropathic pain is epidural spinal cord stimulation (SCS). Despite its proved efficacy, the favourable cost-effectiveness when compared to the long-term use of poorly effective drugs and the expanding array of indications and technical improvements, SCS is still worldwide largely neglected by general practitioners, neurologists, neurosurgeons and pain therapists, often bringing to a large delay in considering as a therapeutic option for patients affected by neuropathic chronic pain. The present state of the art of SCS in the treatment of chronic neuropathic pain is here overviewed and speculations on whether to use a trial period or direct implant, to choose between percutaneous leads or paddle electrodes and on the pros and cons of the different patterns of stimulation presently available on the market (tonic stim, high-frequency stim and burst stim) are described.

17 June 2019 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
VLVincenzo Levi
Vincenzo Levi
RCRoberto Cordella
Roberto Cordella
ADAntonio D’aMmando
Antonio D’aMmando
GTGiovanni Tringali
Giovanni Tringali
IDIvano Dones
Ivano Dones
AFAngelo Franzini
Angelo Franzini

29 August 2022 in Movement Disorders
Verified
Journal Article
Open access
NANico Golfrè Andreasi
Nico Golfrè Andreasi
Roberto CiliaRoberto Cilia
Roberto Cilia
Luigi Michele RomitoLuigi Michele Romito
Luigi Michele Romito
SBSalvatore Bonvegna
Salvatore Bonvegna
GSGiulia Straccia
Giulia Straccia
RERoberto Eleopra
Roberto Eleopra
Background: Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is a safe and effective procedure for drug‐resistant tremor in Parkinson's disease (PD).Objective: The aim of this study was to demonstrate that MRgFUS ventralis intermedius thalamotomy in early‐stage tremor‐dominant PD may prevent an increase in dopaminergic medication 6 months after treatment compared with matched PD control subjects on standard medical therapy.Methods: We prospectively enrolled patients with early‐stage PD who underwent MRgFUS ventralis intermedius thalamotomy (PD‐FUS) and patients treated with oral dopaminergic therapy (PD‐ODT) with a 1:2 ratio. We collected demographic and clinical data at baseline and 6 and 12 months after thalamotomy.Results: We included 10 patients in the PD‐FUS group and 20 patients in the PD‐ODT group. We found a significant increase in total levodopa equivalent daily dose and levodopa plus monoamine oxidase B inhibitors dose in the PD‐ODT group 6 months after thalamotomy.Conclusions: In early‐stage tremor‐dominant PD, MRgFUS thalamotomy may be useful to reduce tremor and avoid the need to increase dopaminergic medications. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

1 March 2020 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
VLVincenzo Levi
Vincenzo Levi
NLNicola Ernesto Di Laurenzio
Nicola Ernesto Di Laurenzio
ITIrene Tramacere
Irene Tramacere
AEAlessandra Erbetta
Alessandra Erbetta
LCLuisa Chiapparini
Luisa Chiapparini
GMGiuseppe Messina
Giuseppe Messina
OBJECTIVE: Although epidural blood patch (EBP) is considered the gold-standard treatment for drug-resistant orthostatic headache in spontaneous intracranial hypotension (SIH), no clear evidence exists regarding the best administration method of this technique (blind vs target procedures). The aim of this study was to assess the long-term efficacy of blind lumbar EBP and predictors on preoperative MRI of good outcome.METHODS: Lumbar EBP was performed by injecting 10 ml of autologous venous blood, fibrin glue, and contrast medium in 101 consecutive patients affected by SIH and orthostatic headache. Visual analog scale (VAS) scores for headache were recorded preoperatively, at 48 hours and 6 months after the procedure, and by telephone interview in July 2017. Patients were defined as good responders if a VAS score reduction of at least 50% was achieved within 48 hours of the procedure and lasted for at least 6 months. Finally, common radiological SIH findings were correlated with clinical outcomes.RESULTS: The median follow-up was 60 months (range 8–135 months); 140 lumbar EBPs were performed without complications. The baseline VAS score was 8.7 ± 1.3, while the mean VAS score after the first EBP procedure was 3.5 ± 2.2 (p < 0.001). The overall response rate at the 6-month follow-up was 68.3% (mean VAS score 2.5 ± 2.4, p < 0.001). Symptoms recurred in 32 patients (31.7%). These patients underwent a second procedure, with a response rate at the 6-month follow-up of 78.1%. Seven patients (6.9%) did not improve after a third procedure and remained symptomatic. The overall response rate at the last follow-up was 89.1% with a mean VAS score of 2.7 ± 2.3 (p < 0.001). The only MRI predictors of good outcome were location of the iter > 2 mm below the incisural line (p < 0.05) and a pontomesencephalic angle (PMA) < 40° (p < 0.05).CONCLUSIONS: Lumbar EBP may be considered safe and effective in cases of drug-refractory SIH. The presence of a preprocedural PMA < 40° and location of the iter > 2 mm below the incisural line were the most significant predictors of good outcome. Randomized prospective clinical trials comparing lumbar with targeted EBP are warranted to validate these results.

9 September 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
NANico Golfrè Andreasi
Nico Golfrè Andreasi
Luigi Michele RomitoLuigi Michele Romito
Luigi Michele Romito
RTRoberta Telese
Roberta Telese
Roberto CiliaRoberto Cilia
Roberto Cilia
AEAntonio Emanuele Elia
Antonio Emanuele Elia
RERoberto Eleopra
Roberto Eleopra

6 October 2015 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
VLVincenzo Levi
Vincenzo Levi
GCGiorgio Carrabba
Giorgio Carrabba
PRPaolo Rampini
Paolo Rampini
MLMarco Locatelli
Marco Locatelli
Patients aged 65 years and older are not traditionally considered optimal candidates for subthalamic deep brain stimulation (STN-DBS), mainly for their presumed increased incidence of surgical complications. The aim of this study was to assess STN-DBS surgery safety in relation to age. A total of 107 consecutive patients undergoing bilateral STN-DBS at our institution between 2002 and 2014 were retrospectively stratified according to age in two groups (Young group < 65 years old; Elderly group ≥ 65 years old;). Rate of short-term surgical complications (within 90 days) was reviewed and compared between the two groups. Pre-operative baseline data were comparable between the two groups. The 90-days post-operative mortality rate was 0%. Overall incidence of complications related to surgery was 6,54%. In the Elderly group we observed 3 post-operative intra-cerebral haematomas (7,89%), 1 requiring urgent surgical evacuation. In the Young group we observed 2 post-operative asymptomatic intra-cerebral haematomas (2,89%) and 2 wound infections (2,89%), 1 requiring system removal. No others surgical complications were noticed in both groups. Chronological age ≥ 65 years old should not be considered alone as exclusion criteria to STN-DBS surgery.